News

August 30, 2017

Automated Medigene System Identifies New Cancer Immunotherapy Targets

News

Medigene has created an automated method for detecting newly created cancer molecules called neoantigens as they arise in a developing tumor. The company believes the high-volume method will prove more ... Read more

August 29, 2017August 29, 2017

Novogen to Initiate Phase 2 Clinical Trial of GDC-0084 Therapy for Gliobastoma by Year’s End

News

A Phase 2 trial evaluating Novogen‘s GDC-0084 therapy in glioblastoma patients should begin by year’s end, the Australian company announced. “The GDC-0084 study is on track to commence this year, in ... Read more

August 28, 2017

CRISPR Teams Up With Massachusetts General Hospital on Gene-editing Immunotherapies

News

Researchers at CRISPR Therapeutics and Massachusetts General Hospital Cancer Center have joined forces to develop T-cell-based cancer immunotherapies using the CRISPR/Cas9 gene editing system. CRISPR/Cas9 allows researchers to alter or silence ... Read more

August 25, 2017

Argos to Present Interim Results of Phase 3 ADAPT Trial for Renal Cell Cancer

News

Interim results from the ongoing Phase 3 ADAPT clinical trial for the investigational therapy Rocapuldencel-T (AGS-003) in patients with metastatic renal cell carcinoma, will be presented at the 2017 Congress ... Read more

August 24, 2017August 24, 2017

Aptevo, Alligator Biosciences to Produce Bispecific Antibody ALG.APV-527 for Future Clinical Trials

News

Aptevo Therapeutics and Alligator Bioscience will jointly manufacture their immunotherapy candidate ALG.APV-527 in order to fulfill the requiremeents of an investigational new drug (IND) application for future human clinical testing. ALG.APV-527, developed using Seattle-based Aptevo’s ... Read more

August 23, 2017

Combination of Pexa-Vec, Checkpoint Inhibitors to Be Tested in Advanced Colon Cancer Trial

News

SillaJen and the National Cancer Institute (NCI) are partnering to test Pexa-Vec in combination with specific checkpoint inhibitors for the treatment of patients with advanced stage colorectal cancer (CRC). The cooperative research and development agreement (CRADA) ... Read more

August 22, 2017

FDA Accepts Investigational New Drug Application for VBI’s Therapy to Treat Brain Cancer

News

The U.S. Food and Drug Administration has accepted VBI Vaccines‘ investigational new drug (IND) application for its immunotherapy VBI-1901, which targets the most common and aggressive form of malignant brain cancer, glioblastoma multiforme ... Read more

August 21, 2017August 21, 2017

American Society of Clinical Oncology Updates Guidelines for Treatment of Advanced Non-Small Cell Lung Cancer

News

The American Society of Clinical Oncology (ASCO) recently updated its clinical guidelines for advanced non-small cell lung cancer (NSCLC) so that oncologists can select the most appropriate treatment for patients. Treatments for ... Read more

August 19, 2017

First Patient with BPDCN Receives UCART123 Dose in Phase 1 Clinical Trial

News

The first patient with Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN) has received a dose of Cellectis’ UCART123 in a Phase 1 clinical trial. UCART123 is a gene edited T-cell drug that ... Read more

August 18, 2017August 18, 2017

Scientists Examine How Anti-CTLA-4 and Anti-PD-1 Checkpoint-Blockade Therapies Fight Cancer Cells

News

Researchers have known that the checkpoint blockade therapies CTLA-4 and PD-1 inhibitors have been clinically successful in treating cancer patients. But they didn’t fully understand how these inhibitors function. A ... Read more